Transforming drug discovery through AI and hiPSCs

Greenstone Biosciences is revolutionizing the field of drug discovery. We leverage cutting-edge human iPSC based New Approach Methods (NAMs) and Artificial Intelligence (AI) technologies using 3D organoids and advanced human micro-physiological systems.

WE ARE GREENSTONE

Deconvoluting diseases

Our mission is transforming drug discovery and accelerating the development of effective therapies for patients.

About us

Greenstone is a platform computational biology startup company at Stanford Research Park, located at Alexandria Center for Life Sciences. Our mission is transforming drug discovery and accelerating the development of effective therapies for patients.

Our history

Greenstone Biosciences, Inc. was established in 2021. We are actively doing bench top science at Alexandria Stanford Research Park, Palo Alto. Co-founder Joseph C. Wu, MD, PhD is the Simon Stertzer Professor of Medicine and Radiology and the Director of Cardiovascular Institute at Stanford University School of Medicine. Founding team members are world class, Stanford, Harvard, and UCLA trained scientists. We are looking to hire top notch scientists who welcome the challenge of getting effective therapies to patients.

Our vision

Our vision is to transform drug discovery from a slow, sequential, and high-failure process into a rapid, integrated, and novel computational platform accelerating drug discovery. We are integrating high performance drug discovery, AI/Machine Learning computing, human induced pluripotent cells (hiPSCs) technology to achieve success.

we are grenstone

WANT TO JOIN US?

Be a part of an ambitious team with limitless potential.

Do you want to be a part of an innovative company that helps patients? If you share our vision contact us.

Follow Us: Twitter logo Linkedin logo

DSC_0449_celine_stair